-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

602.O3.6 602. Myeloid Oncogenesis: Basic: DNA Damage and Genetic Evolution

Symposia: Myeloid Oncogenesis: Basic Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Acute Myeloid Malignancies, AML, Translational Research, CHIP, genomics, hematopoiesis, Chronic Myeloid Malignancies, CMML, Diseases, Myeloid Malignancies, Biological Processes, Technology and Procedures, multi-systemic interactions, omics technologies
Monday, December 12, 2022: 2:45 PM-4:15 PM
293-294 (Ernest N. Morial Convention Center)
Moderators:
Daniel Herranz, PharmD, PhD, The Cancer Institute of New Jersey and Claudia Lengerke, MD, University Hospital Tuebingen
Disclosures:
No relevant conflicts of interest to declare.
Fundamental Research Relating to DNA Damage and Genetic Evolution in Myeloid Oncogenesis.
2:45 PM

Dongxu Jiang, PhD1,2*, Feng Pan, PhD3*, Yihong Guan, PhD1*, Xiaorong Gu, PhD1*, Naomi Kawashima, MD, PhD4,5*, Divya Jyoti Singh, PhD2,4*, Danai Dima, MD1,2, Guangbo Qu, PhD6*, Edward F Greenberg, MD1, Valeria Visconte, PhD4, Omar Mian1*, Mingjiang Xu, MD, PhD3, Jaroslaw P. Maciejewski, MD, PhD, FACP1 and Babal K. Jha, PhD, MPhil, MSc, BSc1,2*

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Center for Immunotherapy & Precision Immuno-Oncology, Cleveland Clinic, Lerner Research Institute, Cleveland, OH
3Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
5Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
6Institute of Urban Environment, Chinese Academy of Sciences, Xiamen, China

3:00 PM

Nana Adjoa Ben-Crentsil1, Ariel Quintana-Gonzalez, PhD1*, Maria E Balasis1*, Hannah Newman, BS1*, Traci L. Kruer, PhD1, Lei Sun, PhD1*, Christopher Letson, BS1, Abhishek Dhawan, PhD1*, Chetasi Talati, MD1*, Meghan Ferrall-Fairbanks, PhD2, Alexis Vedder, BS1*, Kathy L McGraw, Ph.D.3*, Rami S. Komrokji1, Li Ma4* and Eric Padron, MD1

1Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
2J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL
3Center for Cancer Research, National Cancer Institute, Bethesda, MD
4The University of Texas MD Anderson Cancer Center, Houston, TX

3:15 PM

Linda Zhang, BA1,2, Joanne I. Hsu, MD, PhD2,3*, Etienne D. Braekeleer, Ph.D4*, Hidetaka Uryu5*, Elsa Callen-Moreu, PhD6*, Andre Nussenzweig, PhD6*, Koichi Takahashi, MD, PhD7,8, George S Vassiliou, FRCPath, MRCP, PhD, MBBS4 and Margaret A. Goodell, PhD3,9

1Translational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston, TX
2Medical Scientist Training Program, Baylor College of Medicine, Houston
3Translational Biology and Molecular Medicine Graduate Program, Baylor College of Medicine, Houston
4University of Cambridge, Department of Haematology, Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom
5Leukemia Department, The UNIVERSITY of TEXAS, M.D. Anderson, Houston, TX
6Laboratory of Genome Integrity, NIH NCI, Bethesda
7Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
8Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
9Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX

3:30 PM

Nataly Cruz Rodriguez1*, Andriana G. Kotini, PhD2, Saul Carcamo, PhD2*, Malgorzata Olszewska2*, Elsa Bernard, PhD3*, Hanzhi Luo, PhD4*, Michael G Kharas, PhD4, Dan Hasson, PhD2* and Eirini P. Papapetrou, MD, PhD2

1Icahn School of Medicine at Mount Sinai, New York, NY
2Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
4Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY

3:45 PM

Peter van Galen, PhD1, Gabriel K. Griffin, MD2, Christopher A. G. Booth, PhD3, Katsuhiro Togami, MD, PhD3, Sun Sook Chung, PhD3*, Daniel Ssozi, BA1*, Julia A. Verga, BS4*, Juliette M. C. Bouyssou, PhD3*, Yoke Seng Lee, PhD1*, Vignesh Shanmugam, MD5*, Nicole R. LeBoeuf, MD, MPH6*, Elizabeth A. Morgan, MD5, Bradley E. Bernstein, MD, PhD4*, Volker Hovestadt, PhD4* and Andrew A. Lane, MD, PhD3

1Division of Hematology, Brigham and Women's Hospital, Boston, MA
2Department of Pathology, Brigham and Women's Hospital, Newton, MA
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Dana-Farber Cancer Institute, Broad Institute of MIT and Harvard, Boston, MA
5Department of Pathology, Brigham and Women's Hospital, Boston, MA
6Department of Dermatology, The Center for Cutaneous Oncology, Brigham & Women’s Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

4:00 PM

Christopher A. G. Booth, PhD, Juliette M. C. Bouyssou, PhD*, Katsuhiro Togami, MD, PhD and Andrew A. Lane, MD, PhD

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

*signifies non-member of ASH